Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0012833 (
dizziness
)
9,689
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cannabidiol
(
CBD
), a major cannabinoid of hemp, does not bind to CB1 receptors and is therefore devoid of psychotomimetic properties. Under acidic conditions,
CBD
can be transformed to delta9-tetrahydrocannabinol (THC) and other cannabinoids. It has been argued that this may occur also after oral administration in humans. However, the experimental conversion of
CBD
to THC and delta8-THC in simulated gastric fluid (SGF) is a highly artificial approach that deviates significantly from physiological conditions in the stomach; therefore, SGF does not allow an extrapolation to
in vivo
conditions. Unsurprisingly, the conversion of oral
CBD
to THC and its metabolites has not been observed to occur
in vivo
, even after high doses of oral
CBD
. In addition, the typical spectrum of side effects of THC, or of the very similar synthetic cannabinoid nabilone, as listed in the official Summary of Product Characteristics (e.g.,
dizziness
, euphoria/high, thinking abnormal/concentration difficulties, nausea, tachycardia) has not been observed after treatment with
CBD
in double-blind, randomized, controlled clinical trials. In conclusion, the conversion of
CBD
to THC in SGF seems to be an
in vitro
artifact.
...
PMID:A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans. 2886 7
